Friday, July 18, 2014 5:30:57 PM
So what you call stupid was a strategic choice when you are faced with a grow or die scenario, or at least a grow into company that merits public status and is not just a local yokel.
It takes time for new branches to make money, and I suspect that some new branches won't work out and some will do very well, time will tell.
Anyway, the issue isn't revenue growth, it is clear from the numbers rather than the commentary that there has been substantial growth. The issue is when will that growth enable to the Company to start reducing its reliance on the high interest convertible debt. That's the question and the answer to that will determine whether the stock doubles in the next quarter or not.
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM